142 related articles for article (PubMed ID: 18363730)
1. Vitiligo-like hypopigmentation with poliosis following treatment of superficial basal cell carcinoma with imiquimod.
Jacob SE; Blyumin M
Dermatol Surg; 2008 Jun; 34(6):844-5. PubMed ID: 18363730
[No Abstract] [Full Text] [Related]
2. Vitiligo-like depigmentation induced by imiquimod treatment of superficial basal cell carcinoma.
Sriprakash K; Godbolt A
Australas J Dermatol; 2009 Aug; 50(3):211-3. PubMed ID: 19659986
[TBL] [Abstract][Full Text] [Related]
3. Imiquimod-induced depigmentation: report of two cases and review of the literature.
Burnett CT; Kouba DJ
Dermatol Surg; 2012 Nov; 38(11):1872-5. PubMed ID: 22805097
[No Abstract] [Full Text] [Related]
4. Permanent facial hypopigmentation following treatment with imiquimod cream.
Mendonça CO; Yates VM
Clin Exp Dermatol; 2006 Sep; 31(5):721-2. PubMed ID: 16780500
[No Abstract] [Full Text] [Related]
5. Imiquimod-induced vitiligo after treatment of nodular basal cell carcinoma.
Gowda S; Tillman DK; Fitzpatrick JE; Gaspari AA; Goldenberg G
J Cutan Pathol; 2009 Aug; 36(8):878-81. PubMed ID: 19586497
[TBL] [Abstract][Full Text] [Related]
6. Letter: Changes in dermoscopic features in superficial basal cell carcinomas treated with imiquimod.
Micantonio T; Fargnoli MC; Piccolo D; Peris K
Dermatol Surg; 2007 Nov; 33(11):1403-5. PubMed ID: 17958603
[No Abstract] [Full Text] [Related]
7. Giant basal cell carcinoma. Improvement and vitiligo-like hypopigmentation after intermittent treatment with 5% imiquimod.
Urbina F
Acta Dermatovenerol Croat; 2012; 20(4):275-8. PubMed ID: 23317492
[No Abstract] [Full Text] [Related]
8. Efficacy and safety of 5% imiquimod cream in treating patients with multiple superficial basal cell carcinomas.
Marks R; Owens M; Walters SA;
Arch Dermatol; 2004 Oct; 140(10):1284-5. PubMed ID: 15492200
[No Abstract] [Full Text] [Related]
9. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe.
Schulze HJ; Cribier B; Requena L; Reifenberger J; Ferrándiz C; Garcia Diez A; Tebbs V; McRae S
Br J Dermatol; 2005 May; 152(5):939-47. PubMed ID: 15888150
[TBL] [Abstract][Full Text] [Related]
10. 5% imiquimod cream for the treatment of large superficial basal cell carcinoma.
Shumack S; Gebauer K; Quirk C; Macdonald K; Walters SA; Owens M
Arch Dermatol; 2004 Oct; 140(10):1286-7. PubMed ID: 15492202
[No Abstract] [Full Text] [Related]
11. Generalized exacerbation of psoriasis associated with imiquimod cream treatment of superficial basal cell carcinomas.
Rajan N; Langtry JA
Clin Exp Dermatol; 2006 Jan; 31(1):140-1. PubMed ID: 16309513
[No Abstract] [Full Text] [Related]
12. Clearance of basal cell and superficial squamous cell carcinomas after imiquimod therapy.
Warshauer E; Warshauer BL
J Drugs Dermatol; 2008 May; 7(5):447-51. PubMed ID: 18505136
[TBL] [Abstract][Full Text] [Related]
13. Open study of the efficacy and mechanism of action of topical imiquimod in basal cell carcinoma.
Vidal D; Matías-Guiu X; Alomar A
Clin Exp Dermatol; 2004 Sep; 29(5):518-25. PubMed ID: 15347339
[TBL] [Abstract][Full Text] [Related]
14. Two-year interim results from a 5-year study evaluating clinical recurrence of superficial basal cell carcinoma after treatment with imiquimod 5% cream daily for 6 weeks.
Quirk C; Gebauer K; Owens M; Stampone P
Australas J Dermatol; 2006 Nov; 47(4):258-65. PubMed ID: 17034468
[TBL] [Abstract][Full Text] [Related]
15. Recurrence rate of superficial basal cell carcinoma following successful treatment with imiquimod 5% cream: interim 2-year results from an ongoing 5-year follow-up study in Europe.
Gollnick H; Barona CG; Frank RG; Ruzicka T; Megahed M; Tebbs V; Owens M; Stampone P
Eur J Dermatol; 2005; 15(5):374-81. PubMed ID: 16172048
[TBL] [Abstract][Full Text] [Related]
16. Imiquimod and pulmonary embolism: a case report.
Leroy B; Richez A; Wolf F; Descotes J; Vial T
Therapie; 2014; 69(2):180-1. PubMed ID: 24926639
[TBL] [Abstract][Full Text] [Related]
17. The appearance of inflammatory papules in the skin surrounding areas treated with imiquimod cream for basal cell carcinoma.
Stinco G; Frattasio A; Forcione M; Quinkenstein E; Finato N; Patrone P
Br J Dermatol; 2008 Feb; 158(2):408-9. PubMed ID: 18028501
[No Abstract] [Full Text] [Related]
18. Has imiquimod 5% cream a role in the management of recurrent basal cell carcinoma?
RUIZ-VILLAVERDE R; SANCHEZ-CANO D; BURKHARDT-PEREZ P; SINTES RN
Eur J Dermatol; 2009; 19(5):481-3. PubMed ID: 19527989
[TBL] [Abstract][Full Text] [Related]
19. Rhabdomyolysis and capillary leak syndrome in a patient treated with topical imiquimod.
Norum HM; Kolberg ES; Solhaug V; Nordal K; Aukrust P
Int J Dermatol; 2016 Sep; 55(9):1030-2. PubMed ID: 27061736
[No Abstract] [Full Text] [Related]
20. Treatment of all basal cell carcinoma variants including large and high-risk lesions with 5% imiquimod cream: histological and clinical changes, outcome, and follow-up.
Schiessl C; Wolber C; Tauber M; Offner F; Strohal R
J Drugs Dermatol; 2007 May; 6(5):507-13. PubMed ID: 17679185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
